Annette M. Staiger

Feasibility of Patient-Derived 3D Gastrointestinal Stromal Tumour Models as Alternatives for In Vivo Mouse Models

Integration of high-throughput proteomic data and complementary omics layers with PriOmics

Genetic Characterization of Primary Mediastinal B-Cell Lymphoma: Pathogenesis and Patient Outcomes

Frequent ZNF217 mutations lead to transcriptional deregulation of interferon signal transduction via altered chromatin accessibility in B cell lymphoma

PriOmics: integration of high-throughput proteomic data with complementary omics layers using mixed graphical modeling with group priors

PARP14 is a novel target in STAT6 mutant follicular lymphoma

S101: GENETIC AND EPIGENETIC FACTORS DRIVING PRIMARY MEDIASTINAL B-CELL LYMPHOMA PATHOGENESIS AND OUTCOME

Genetic mechanisms of HLA-I loss and immune escape in diffuse large B cell lymphoma

Molecular and functional profiling identifies therapeutically targetable vulnerabilities in plasmablastic lymphoma

Epstein–Barr virus status of sporadic Burkitt lymphoma is associated with patient age and mutational features

SPARC-positive macrophages are the superior prognostic factor in the microenvironment of diffuse large B-cell lymphoma and independent of MYC rearrangement and double-/triple-hit status

Evaluating upfront high-dose consolidation after R-CHOP for follicular lymphoma by clinical and genetic risk models

Cytokeratin expression in plasmablastic lymphoma – a possible diagnostic pitfall in the routine work‐up of tumours

Identification of a miRNA based model to detect prognostic subgroups in patients with aggressive B-cell lymphoma

A novel lymphoma-associated macrophage interaction signature (LAMIS) provides robust risk prognostication in diffuse large B-cell lymphoma clinical trial cohorts of the DSHNHL

Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes

Duodenal-type and nodal follicular lymphomas differ by their immune microenvironment rather than their mutation profiles

Author Correction: Molecular subtypes of diffuse large B celllymphoma are associated with distinct pathogenic mechanisms and outcomes

PARP14 Is a Novel Therapeutic Target in STAT6 mutant Follicular Lymphoma

A New Stromal Signature Applicable to Formalin-Fixed Paraffin-Embedded Tissues Identifies Patients at Risk in Prospective Clinical Trials of the German High-Grade Non-Hodgkin Lymphoma Study Group

<i>TP53</i> mutation and survival in aggressive B cell lymphoma

Advanced patient age at diagnosis of diffuse large B-cell lymphoma is associated with molecular characteristics including ABC-subtype and high expression of MYC

The Mutational Landscape and Immune Microenvironment of Primary Intestinal Follicular Lymphoma (PIFL)

Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy

Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry

Anti-CD22 and anti-CD79B antibody drug conjugates are active in different molecular diffuse large B-cell lymphoma subtypes